15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Pliant Therapeutics Inc, 1 rate it Buy or better, 2 sit at Hold, and 1 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $3.00 to $3.00, so the covering firms are broadly aligned. The average target of $3.00 sits 178% above the current $1.08. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.36 next quarter toward $-0.81 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Hold
Strong Buy00%
Buy125%
Hold250%
Sell125%
Strong Sell00%
Based on 4 analysts giving stock ratings to Pliant Therapeutics Inc.
As of Jul, 1 of 4 firms rate PLRX a Buy (2 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
PLRX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.36
Range $-0.42 – $-0.32 · 4 analysts · -15% YoY
Next period, 4 analysts expect Pliant Therapeutics Inc to earn $-0.36 a share (range $-0.42 – $-0.32), versus $-0.43 a year earlier. Full-year consensus is $-1.41, growing to $-0.81 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $3.8M next year.
Top analysts covering Pliant Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PLRX.
#1
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$3.00+177.8% to target
Overall win rate
34%
+ Follow
#2
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #232
Hold
No targeton PLRX
Overall win rate
34%
+ Follow
#3
Brian Abrahams
RBC Capital · Rank #311
Hold
$2.00+85.2% to target
Overall win rate
25%
+ Follow
#4
Brian Cheng
JP Morgan
Sell
No targeton PLRX
Coverage
—
+ Follow
#5
David Lebowitz
Citigroup
Hold
$1.70+57.4% to target
Coverage
—
+ Follow
PLRX stock forecast FAQ
What is PLRX's average 12-month price target?+
The 2 analysts with a live target average $3.00 for Pliant Therapeutics Inc over the next 12 months, ranging from a $3.00 high to a $3.00 low.
Is PLRX stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 4 analyst ratings, 1 are Buy or Strong Buy, 2 are Hold, and 1 are Sell or Strong Sell.
How many Wall Street analysts cover PLRX?+
4 analysts have an active rating on Pliant Therapeutics Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering PLRX?+
Among analysts who currently cover PLRX, Yasmeen Rahimi of Piper Sandler has the strongest overall Quantellect track record (Rank #152). Their current call is Buy with a $3.00 target.
What is Pliant Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.36 per share (range $-0.42 – $-0.32) across 4 analysts. Full-year EPS is projected at $-1.41, rising to $-0.81 the following year.
How much revenue is Pliant Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $3.8M next year.
Have analysts been upgrading or downgrading PLRX lately?+
As of Jul, 1 of 4 firms rate PLRX a Buy (2 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PLRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
